From Northvolt’s staggering $14bn failure to crypto crashes and biotech struggles, 2024 has been a brutal year for corporate-backed startups facing financial, operational, and market pressures.
Failure rates of investments in venture portfolios vary widely, largely influenced by differing definitions of “failure” and the industry’s persistent shroud of secrecy. University of Pennsylvania professor Elizabeth Pollman cites estimates that around 75% of venture-backed startups fail to provide returns to all equity holders. Some more optimistic and forgiving estimates suggest a comparatively…
